PUBLIC NOTICE: Environmental clearance is accorded to M/s. Neuland Laboratories Limited, Unit-3, Sy.No.10, Plot No.3-72, Gaddapotharam (V), Jinnaram (M), Sangareddy District Telangana State by Ministry of Environment Forests & Climate Change, Government of India for the expansion of production capacity of Synthetic Organic Chemicals vide order no. SEIAA/TS/OL/SGRD-49/2018-944 dated 26.04.2018. The copy is available in the office of Telangana State Pollution Control Board and MoEF website www.envfor.nic.in Management of Neuland Laboratories Limited.
The Neuland sales team was actively talking with clients and would-be clients at CPhI North America. The big news was that Neuland has added a third facility and are getting it ready to add to the family. Strategic planning for the future is incredibly important, so our conversations with clients were on the topics of future trends and therapeutic need, as well as existing campaigns. Even in this digital age, there is no substitute for face to face interaction!
(5th March 2018)
Jitsubo Co., Ltd. Has announced that it has entered into a strategic collaboration in peptide research with Neuland Health Sciences Private Limited. A Memorandum of Understanding was signed on March 5th, 2018, with the goal of establishing a long-term partnership focusing on research and commercial development in the field of peptide APIs.
“Jitsubo’s Molecular Hiving technology can bring about a strong cost advantage. Combining Jitsubo’s Molecular Hiving technology with Neuland’s specialized purification technology and peptide capabilities, we aim at jointly developing peptide APIs. We recognize clear competitive advantages of the partnership in the growing peptide market. This collaboration, which is a mutually complementary relationship, implies a huge potential”, said Kazuaki Kanai, CEO of Jitsubo.
“We are seeing an increasing demand for value-added peptides and for peptides incorporating non-natural amino acids.” said Davuluri Saharsh Rao, Director, NHSPL. “The goal of our collaboration is to contribute to the global healthcare industry by providing high-quality but affordable peptides to the market. I am confident that this global alliance between a Japanese company with a high technological edge and an Indian company with extensive experience and capabilities in peptide will create a great synergy.”
Further, the Jitsubo-Neuland partnership creates opportunity for an exploratory research and development collaboration in peptide where Jitsubo’s Molecular Hiving technology could be complementary to Neuland’s strength in peptide manufacturing (using Solid, Solution, Hybrid phase) and its proprietary purification technology.
You can read the full press release here.
Neuland has brought online a fully operational dedicated Process Engineering Lab at its R&D Center. The new lab includes state-of-the-art instrumentation, systems and innovative devices to support operations and safety studies using a QbD approach.
“Our new Process Engineering Lab integrates the key attributes of QbD process understanding, process control, and continuous improvement with advanced equipment, Design of Experiments Software, and Design Space methodology, to optimize process design, operations, and productivity,” says Saharsh Davuluri, Joint Managing Director at Neuland.
Neuland’s new Process Engineering Lab includes a stirred, controlled HEL reaction calorimeter that measures the rate of heat release during reactions. Automated parallel HEL reactors enable a chemist to perform multiple experiments at temperatures ranging from -60 to 225oC. The lab’s new Thermal Screening Unit (TSU) indicates the thermal stability of chemicals and safe processing temperatures. Ideal for risk analysis, the TSU uses only 0.5-5 g of sample.
“This important addition to our capabilities will better enable Neuland to develop cost-effective procedures and quality products, meet regulatory requirements, improve scale-up efficiency, and accelerate time to market,” says Dr. Ravi Ponnaiah, President – Science & Technology.
A QbD approach includes three fundamental elements: 1) a clear understanding of the target product profile; 2) determination of critical quality attributes (CQAs) and 3) ensuring that processes and products remain within defined range limits.
Continual risk assessment of all aspects of a process, from the quality of the raw materials to the process parameters and their potential effects on CQAs enables continuous improvement of processes and products. A QbD program relies on applying this information to develop a design space and a process control strategy, continually monitoring the process to assess its capabilities, introducing changes to improve product quality, cost, and process efficiency.
You can read the full press release here.
Neuland, as a pharma company, is committed to impacting life positively across the globe. Whether it is manufacturing the products or improving the life of its employees, our focus on ‘quality’ is supreme and is reflected in our CSR activities as well.
The recent ‘conversation-over-tea’ session conducted on 3rd July in our R&D center by Senior HR Manager, Mr. Shiva Kumar, is an instance of our commitment towards Corporate Social Responsibility. The topic was to mull over the issue of food wastage, how we can help in reducing it and in turn contribute towards the global movement of eradicating hunger and food wastage.
Food-wastage-awareness posters were recently put up at all the Neuland facilities. In R&D, Mr. Shiva Kumar arranged for an interactive session during an afternoon tea-break to create awareness among Neulanders, so that they could come together in fighting food-wastage. Each of the participants was given the poster to read out the data on it, ponder over the information and then share their thoughts with everyone.
The result was a collective effort and an astounding reduction of food-wastage by almost 75% from the very next day!
Saharsh Davuluri was interviewed for the ‘Show Daily’ magazine that was freely distributed at the inaugural CPhI North America / InformEx 2017 show, held in Philadelphia last month.
Click here to read the interview with our Joint Managing Director that appeared in the publication.
On the occasion of 43rd World Environment Day celebrated on 5 June, 2017, as a responsible organization, we conducted various programs to create an awareness among the employees about protection of our environment.
This year in addition to the plantation and other programs, we organized a rally in Bonthapally where 125 NLL employees from Unit I and R&D participated. Unit II employees participated in a rally organized by TSPCB & TSIIC in Pashamylaram.
Neuland’s efforts to spread awareness about the importance and protection of our environment was hugely appreciated and the programs were published in two Telugu newspapers.
The 3-day event, held May 15-18th at the Philadelphia Convention Center in Pennsylvania, was a great success for the Neuland North America team. There were a lot of visitors to our exhibition booth showing interest in Neuland and seeing what we had to offer, and opening opportunities of doing even more business in the world’s biggest pharma market.
The team also welcomed the chance to meet with other exhibitors and network with both familiar and new faces around the Convention Center. The relaxed environment of this show made it easy for everyone to get the most out of what CPhI North America/Informex had to offer. All worked together to make this conference a successful event.
Quality is of utmost importance. Focusing on quality in every step of manufacturing, Neuland boasts of two USFDA and EU GMP-compliant manufacturing facilities. Read more about our stringent quality control in the article “No Compromise APIs” on the Pharmaceutical Manufacturing website by clicking here
To stay ahead of the evolving needs and demands of the pharmaceutical and biotechnology industries the contract manufacturing organizations (CMOs), need to continuously adapt new trends. Saharsh Davuluri, Joint Managing Director, sheds light on the changes in the API manufacturing and how a CMO can adapt to the changes in the article “Navigating the Shifting Landscape of Contract API Manufacturing” on the Contract Pharma website. You can read the article by clicking here
Neuland recently sponsored the above-mentioned webinar on Liquid Chromatography. You can view an executive summary of the webinar by downloading this PDF file (Adobe Acrobat required) or view the webcast in full (on-demand) by completing the registration details here.
With the hype now behind us we can confirm that CPhI 2016 in Barcelona proved to be a fantastic success for Neuland. Our hugely impressive stand witnessed a continuous stream of customers for most of the three days. In particular, the “100% API Provider” campaign proved to be a great hit. It was quite refreshing to see that Neuland continues to be a 100% API producer while many competitors were showcasing mixed messages. We responded to every opportunity enthusiastically and this event proved that we put our customers at the centre of our thoughts.
Many of the 20,000 people using the Fira metro station noticed the high impact Neuland advertisements. It proved to be a massive awareness generator for the already well-known Neuland brand, as lots of our customers commented they had seen them.
We also held an after show event at the History Museum in central Barcelona for our VIP customers, who were treated to a wonderful display of over 2000 years of the city’s history.
A big thank you to all customers and staff who collaborated, as you may expect, with a lot of hard work and diligence to make CPhI 2016 the success it was.
Sometimes the obvious focus of your business needs reinforcing with a strong message and this was definitely the case at this year’s CPhI exhibition in Madrid. Neuland took out a powerful advertising campaign on the illuminated panels at the central metro station next to the CPhI exhibition halls. In addition, our API message was beamed out to 48,000 attendees in the ‘Show Daily’ e-newsletter.
The campaign reinforces our credentials as one of the few established main API players who focus entirely on API for clients. It is so easy to get distracted by FDF or selling directly to the market to improve margins. Sometimes this can prove at odds with clients and partners who like to see a clear division between trade suppliers and those that inhabit the same direct marketing space.
As per usual at Neuland, we tried to make our Land of Opportunity different to those that love to see rows of reactors. We understand that people have the equipment and they produce molecules of varying complexity. We are happy with what we can achieve for clients because we have world-class peptide R&D and CMS which complements our formidable reactor capacity.
The human capital at Neuland is what makes this land of real opportunity for clients as well as for would be starters in the industry.
We would like to thank everyone who came to visit us at CPhI in Paris. The show was a great success and we look forward to seeing you all again soon. Below are some photos from this year’s event.